José Baselga
Credentials: · · · ·
History
- 1990–1992
- 1982–1985
Vall d’Hebron University Hospital
- 1978–1982
Research
New England Journal of Medicine · 2001 · 8,905 citations
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
New England Journal of Medicine · 2005 · 3,935 citations
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
New England Journal of Medicine · 2006 · 3,932 citations
- DH
36 papers
28 papers
- LN
28 papers
28 papers
- CH
27 papers
19 papers
- NR
19 papers
- ML
18 papers
Grants
- 2015–2020
Unraveling Resistance to PI3K-Alpha Inhibitors in Breast Cancer
National Cancer Institute · R01
Contact PI · $1.3M · Sloan-Kettering Inst Can Research
Clinical trials
- 2009–2015
Principal investigator · Completed · Phase 1, Phase 2
AstraZeneca
- 2007–2011
Principal investigator · Completed · Phase 2
Merck KGaA, Darmstadt, Germany
- 2012–2015
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Study chair · Completed · Phase 2
SOLTI Breast Cancer Research Group
- 2001
Study chair · Completed · Phase 3
European Organisation for Research and Treatment of Cancer - EORTC